Cited 0 times in Scipus Cited Count

Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer

DC Field Value Language
dc.contributor.authorCho, O-
dc.contributor.authorNoh, OK-
dc.contributor.authorOh, YT-
dc.contributor.authorChang, SJ-
dc.contributor.authorChun, M-
dc.date.accessioned2018-08-24T01:49:54Z-
dc.date.available2018-08-24T01:49:54Z-
dc.date.issued2017-
dc.identifier.issn0250-7005-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/16081-
dc.description.abstractBACKGROUND/AIM: To investigate whether high-dose-rate (HDR) intracavitary brachytherapy (IBT) dose ratios can predict treatment outcomes in patients with stage IIB cervical cancer.
PATIENTS AND METHODS: Ninety-three patients treated with weekly cisplatin-based concurrent chemoradiotherapy and HDR IBT were analyzed. Potential prognostic factors and treatment outcomes were compared between low-HDR-IBT-ratio (0.43) groups, and univariate and multivariate analyses were performed.
RESULTS: Five-year disease-specific survival (DSS) and progression-free survival (PFS) rates were significantly shorter in the low-compared to the high-HDR-IBT-ratio group. A high HDR IBT ratio was confirmed as an independent prognostic factor for DSS and PFS.
CONCLUSION: A high HDR IBT dose ratio improves DSS and PFS in patients with stage IIB cervical cancer. Therefore, active administration of HDR IBT beyond previously accepted levels may be necessary for the treatment of locally advanced cervical cancer.
-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents-
dc.subject.MESHBrachytherapy-
dc.subject.MESHChemoradiotherapy-
dc.subject.MESHCisplatin-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUterine Cervical Neoplasms-
dc.titleClinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer-
dc.typeArticle-
dc.identifier.pmid28011510-
dc.contributor.affiliatedAuthor조, 오연-
dc.contributor.affiliatedAuthor노, 오규-
dc.contributor.affiliatedAuthor오, 영택-
dc.contributor.affiliatedAuthor장, 석준-
dc.contributor.affiliatedAuthor전, 미선-
dc.type.localJournal Papers-
dc.identifier.doi10.21873/anticanres.11325-
dc.citation.titleAnticancer research-
dc.citation.volume37-
dc.citation.number1-
dc.citation.date2017-
dc.citation.startPage327-
dc.citation.endPage334-
dc.identifier.bibliographicCitationAnticancer research, 37(1). : 327-334, 2017-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1791-7530-
dc.relation.journalidJ002507005-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse